Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.

Bachert, Claus; Sousa, Ana R; Han, Joseph K; Schlosser, Rodney J; Sowerby, Leigh J; Hopkins, Claire; Maspero, Jorge F; Smith, Steven G; Kante, Oliver; Karidi-Andrioti, Despina E; Mayer, Bhabita; Chan, Robert H; Yancey, Steve W; Chaker, Adam M

doi:10.1016/j.jaci.2021.10.040

2022

Back
Back to start of result list
Permanent link for displayed object

Title:: Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Document type:: Article; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Author(s):: Bachert, Claus; Sousa, Ana R; Han, Joseph K; Schlosser, Rodney J; Sowerby, Leigh J; Hopkins, Claire; Maspero, Jorge F; Smith, Steven G; Kante, Oliver; Karidi-Andrioti, Despina E; Mayer, Bhabita; Chan, Robert H; Yancey, Steve W; Chaker, Adam M
Abstract:: BACKGROUND: In the phase III SYNAPSE study, mepolizumab reduced nasal polyp (NP) size and nasal obstruction in chronic rhinosinusitis with NP. OBJECTIVE: We sought to assess the efficacy of mepolizumab in patients from SYNAPSE grouped by comorbid asthma, aspirin-exacerbated respiratory disease (AERD), and baseline blood eosinophil count (BEC). METHODS: SYNAPSE, a randomized, double-blind, 52-week study (NCT03085797), included patients with severe bilateral chronic rhinosinusitis with NP eligible for surgery despite intranasal corticosteroid treatment. Patients received 4-weekly subcutaneous mepolizumab 100 mg or placebo plus standard of care for 52 weeks. Coprimary end points were change in total endoscopic NP score (week 52) and nasal obstruction visual analog scale score (weeks 49-52). Subgroup analyses by comorbid asthma and AERD status, and post hoc by BEC, were exploratory. RESULTS: Analyses included 407 patients (289 with asthma; 108 with AERD; 371 and 278 with BEC counts ≥150 or ≥300 cells/μL, respectively). The proportion of patients with greater than or equal to 1-point improvement from baseline in NP score was higher with mepolizumab versus placebo across comorbid diseases (asthma: 52.9% vs 29.5%; AERD: 51.1% vs 20.6%) and baseline BEC subgroups (<150 cells/μL: 55.0% vs 31.3%; ≥150 cells/μL: 49.5% vs 28.1%; <300 cells/μL: 50.7% vs 29.0%; ≥300 cells/μL: 50.4% vs 28.1%). A similar trend was observed in patients without comorbid asthma or AERD. More patients had more than 3-point improvement in nasal obstruction VAS score with mepolizumab versus placebo across comorbid subgroups. CONCLUSIONS: Mepolizumab reduced polyp size and nasal obstruction in chronic rhinosinusitis with NP regardless of the presence of comorbid asthma or AERD.
Journal title abbreviation:: J Allergy Clin Immunol
Year:: 2022
Journal volume:: 149
Journal issue:: 5
Pages contribution:: 1711-1721.e6
Fulltext / DOI:: doi:10.1016/j.jaci.2021.10.040
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/35007624
Print-ISSN:: 0091-6749
TUM Institution:: Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde (Prof. Wollenberg); Lehrstuhl für Molekulare Allergologie und Umweltforschung (Prof. Schmidt-Weber)
BibTeX